Terminated PHASE2 INTERVENTIONAL NCT00082459

Trial to Compare the Routes of Administration of an Investigational, Personalized, Therapeutic Cancer Vaccine Oncophage (HSPPC-96) in Patients With Metastatic Renal Cell Carcinoma

A Randomized Phase II Study Investigating the Route of Administration of Oncophage (HSPPC-96) in Patients With Metastatic Renal Cell Carcinoma

Sponsor: Agenus Inc.

Conditions Renal Cell Carcinoma

Interventions autologous human tumor-derived HSPPC-96

Updated 5 times since 2017 Last updated: Sep 6, 2012 Started: Jul 31, 2002 Primary completion: Dec 31, 2005 Completion: Dec 31, 2005

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

Terminated

Lack of enrollment

Other terminated trials from Agenus Inc.

More terminations from Agenus Inc.

Other Renal Cell Carcinoma trials with similar outcome

Browse all Renal Cell Carcinoma trials

A PHASE2 clinical study on Renal Cell Carcinoma, this trial is terminated or withdrawn. The trial is conducted by Agenus Inc. and has accumulated 5 data snapshots since 2002. Oncology trials at this stage typically focus on safety, tolerability, and early efficacy signals.

Status Flow

Change History

5 versions recorded

Sep 2024 — Present [monthly]

Terminated PHASE2
Jul 2024 — Sep 2024 [monthly]

Terminated PHASE2
Jan 2021 — Jul 2024 [monthly]

Terminated PHASE2
Jun 2018 — Jan 2021 [monthly]

Terminated PHASE2
Jan 2017 — Jun 2018 [monthly]

Terminated PHASE2

First recorded

Jul 2002

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

Agenus Inc.

Data source: Agenus Inc.

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

• Houston, United States